作者
Eugene J Koay, Mark J Truty, Vittorio Cristini, Ryan M Thomas, Rong Chen, Deyali Chatterjee, Ya’an Kang, Priya R Bhosale, Eric P Tamm, Christopher H Crane, Milind Javle, Matthew H Katz, Vijaya N Gottumukkala, Marc A Rozner, Haifa Shen, Jeffery E Lee, Huamin Wang, Yuling Chen, William Plunkett, James L Abbruzzese, Robert A Wolff, Gauri R Varadhachary, Mauro Ferrari, Jason B Fleming
发表日期
2014/3/10
期刊
The Journal of clinical investigation
卷号
124
期号
4
出版商
American Society for Clinical Investigation
简介
Background. The therapeutic resistance of pancreatic ductal adenocarcinoma (PDAC) is partly ascribed to ineffective delivery of chemotherapy to cancer cells. We hypothesized that physical properties at vascular, extracellular, and cellular scales influence delivery of and response to gemcitabine-based therapy.
Methods. We developed a method to measure mass transport properties during routine contrast-enhanced CT scans of individual human PDAC tumors. Additionally, we evaluated gemcitabine infusion during PDAC resection in 12 patients, measuring gemcitabine incorporation into tumor DNA and correlating its uptake with human equilibrative nucleoside transporter (hENT1) levels, stromal reaction, and CT-derived mass transport properties. We also studied associations between CT-derived transport properties and clinical outcomes in patients who received preoperative gemcitabine-based …
学术搜索中的文章
EJ Koay, MJ Truty, V Cristini, RM Thomas, R Chen… - The Journal of clinical investigation, 2014